New combo could spare rectal cancer patients from radiation side effects
NCT ID NCT04215731
First seen Mar 10, 2026 · Last updated May 15, 2026 · Updated 8 times
Summary
This phase 3 trial tests whether a stronger chemotherapy regimen plus a targeted drug (bevacizumab) can replace standard chemoradiation for high-risk locally advanced rectal cancer. About 582 adults will be randomly assigned to one of two treatments. The goal is to see if the new approach improves disease-free survival and reduces the need for radiation, which can cause long-term side effects like pain and incontinence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Sixth Affiliated Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510655, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.